Kalshi Draws $128,401 on 12-Plus Drug-Trial Bets as Critics Warn of Insider Risks
Updated
Updated · Forbes · Jul 16
Kalshi Draws $128,401 on 12-Plus Drug-Trial Bets as Critics Warn of Insider Risks
3 articles · Updated · Forbes · Jul 16
Summary
$128,401 in trading hit Kalshi's new medicine market by Thursday afternoon, with bettors wagering on more than a dozen Phase 3 trial outcomes and FDA approval decisions.
The exchange launched the contracts with AppliedXL and limited them to late-stage trials by established biopharma companies and full FDA approvals, excluding early-stage studies and conditional clearances for now.
Available markets include Gilead's anito-cel, Eli Lilly's retatrutide and whether a Type 1 diabetes cure wins FDA approval before 2033; 56% of bettors currently say no.
Kalshi says employment verification and insider-information restrictions will protect the market and make opaque drug-development odds public, but bioethicists and researchers warn traders with privileged knowledge could manipulate studies or profit before results are released.
As betting on drug trials grows, where is the line between market insight and gambling on human health?
Facing a potential ban on its core business, is Kalshi's biopharma expansion a brilliant pivot or a desperate gamble?
In the race to predict drug success, will the wisdom of the crowd be outsmarted by artificial intelligence?
Kalshi and AppliedXL Launch $24B Clinical Trial Prediction Markets: AI, Ethics, and the Future of Biotech Betting
Overview
In July 2026, Kalshi and AppliedXL launched new prediction markets for betting on biotech clinical trials and drug approvals, aiming to bring transparency to a sector where the odds of drug success are usually hidden and information is often incomplete. Developing a drug is extremely costly, and companies’ futures can depend on a single trial, yet most success estimates remain confidential. Kalshi’s markets address this information gap by creating a real-time, public consensus on drug prospects. AppliedXL’s AI-driven prediction system adds nuance by analyzing trial outcomes beyond simple success or failure, offering more detailed and relevant forecasts for investors and the public.